A gene encoding charybdotoxin (CTX), a K+ channel blocker from scorpion venom, was designed, synthesized, and expressed as a cleavable fusion protein in Escherichia coli. A sequence-specific protease, factor Xa, was used to cleave the fusion protein and thus release the toxin peptide. The recombinant toxin was purified, oxidized to form disulfide bonds, and treated to form N-terminal pyroglutamate. Recombinant CTX is identical to the native venom CTX with respect to high-performance liquid chromatography mobility, amino acid composition, and N-terminal modification. With single Ca2+-activated K+ channels as an assay system, recombinant CTX shows blocking and dissociation kinetics identical to the native venom toxin. The synthetic gene and high-level expression of functionally active CTX make it possible to study the fundamental mechanism of the toxin-ion channel interaction.
kidney (6) , and erythrocytes (7, 8) ; in addition, CTX blocks voltage-activated K+ channels from a variety of sources (5, 7, (9) (10) (11) (12) . In all cases, CTX inhibits in the nanomolar concentration range by binding to the external part of the K+ channel. Inhibition of the channel is known to be due to the physical occlusion of the channel's conduction pathway by the toxin (13) (14) (15) . Because the channel-toxin interaction is mechanistically understood, CTX has proven to be an informative probe of the external "mouth" of K+ channels (16) (17) (18) .
The amino acid sequence of CTX, determined by peptide sequencing (19) , is shown in Fig. 1 . The toxin is a 37-residue polypeptide of 4.3 kDa, with eight positively charged residues, two negative charges, three disulfide bonds, and a blocked N terminus formed by a pyroglutamate residue. The three-dimensional structure of the toxin is known (20) . Built on a foundation of a three-strand antiparallel f3-sheet, the molecule is roughly ellipsoidal, with major and minor axes of 2.5 nm and 1.5 nm, respectively. The functional groups show a remarkable spatial segregation on the surface of the toxin; one face of the molecule is strongly polar, whereas most of the hydrophobic groups project off the opposite face.
Electrophysiological studies have yielded information about the mechanism of toxin block, but it has been difficult to probe the toxin biochemically. Purification ofCTX from its native source is costly and yields only a small amount of protein. In addition, because of lack of specificity ofchemical modifications, information on the functions of specific residues is nonexistent. To overcome this problem, we have developed a system to produce large quantities of genetically manipulable CTX.
We have designed a synthetic gene for CTX and have achieved its high-level expression in Escherichia coli by using a cleavable fusion protein strategy. The following three in vitro posttranslational processing steps were required to yield fully functional CTX: (i) proteolytic cleavage of the CTX coding sequence, (ii) oxidation of the six cysteine residues to form three disulfide bonds, and (iii) formation of N-terminal pyroglutamate. This system will permit a close mechanistic study of the toxin-K+ channel interaction by a combination of reconstitution of single K+ channels and site-directed mutagenesis of CTX.
MATERIALS AND METHODS
Bacterial Strains and Plasmids. E. coli DH1 was used for plasmid propagation and BL21(DE3) was used for the expression of the gene 9-X,-CTX fusion protein.
is a A lysogen of BL21 wherein the prophage contains the RNA polymerase gene of T7 bacteriophage under the control of the lacUV5 promoter (21) . Plasmid pSR9, a vector for producing fusion proteins with the gene 9 protein of T7 bacteriophage, was obtained from K. M. Blumenthal (22) .
Design, Synthesis, and Construction ofa CTX Gene. A DNA sequence encoding the CTX peptide was designed to contain the maximum number ofunique restriction enzyme sites. The gene was constructed from four overlapping oligonucleotide pairs, each of approximately 45 base pairs. Each oligonucleotide was chemically synthesized on an Applied Biosystems model 380A DNA synthesizer, gel-purified, and phosphorylated. The eight oligonucleotides were annealed and ligated using T4 DNA ligase. The synthetic CTX gene, which is flanked by Sal I and HindIII sites, was inserted into pSR9 for the gene 9-Xa-CTX construction pCSP105. After cloning, the sequence of the synthetic CTX gene was confirmed by DNA sequencing of both strands. General rules and constraints for producing synthetic genes were followed (23) .
Expression and Purification of CTX Fusion Protein. E. coli BL21(DE3) cells harboring pCSP105 were grown at 37°C in LB medium in the presence of ampicillin (100 ,ug/ml). Fusion protein synthesis was induced at late logarithmic phase (OD650, 0.8 to 1.0) by the addition of 0.5 mM isopropyl B-D-thiogalactoside (IPTG). Cells were harvested 2-3 hr later, washed, and resuspended in 50 ml of 10 mM Tris HCI, pH 8.0/50 mM NaCl/2 mM Na2EDTA. Lysozyme was added to 2 mg/ml and, after 20 min on ice, 2-mercaptoethanol, phenylmethylsulfonyl fluoride, pepstatin, and leupeptin were added to final concentrations of 10 mM, 1 mM, 1 and factor Xa recognition sequence is underlined (J-_hj-QIY-Arg). tion, the precipitate was dissolved in 10 ml of 50 mM Tris-HCI, pH 7.0/50 mM NaCI/5 mM 2-mercaptoethanol and dialyzed against 2 liters of the same buffer. The dialysate was fractionated on a DEAE-cellulose (2.5 x 12 cm, DE52, Whatman) column with the same buffer by using a 0.05 M-0.5 M NaCI linear gradient (total volume, 300 ml). Fusion protein fractions were pooled, concentrated, stored at -20°C.
Fusion Protein Cleavage by Factor X. The DEAE-cellulosepurified fusion protein pool was dialyzed against 2 liters of 50 mM Tris HCI, pH 8.3/150 mM NaCl/0.5 mM 2-mercaptoethanol. After dialysis, 3 mM CaC12 was added. CTX was cleaved from the fusion protein by factor Xa (restriction protease factor Xa, Boehringer Mannheim, 10 ,ug/mg of fusion protein) at room temperature for up to 36 hr. The digestion mixture was loaded on a Mono-S FPLC column equilibrated with 30 mM sodium phosphate (pH 7.5). Material was eluted with a total of 20 ml of a 0-0.6 M NaCl linear gradient.
N-Terminal Cyclization and Purification of Recombinant CTX. To cyclize the N-terminal glutamine, 5% (vol/vol) acetic acid was added to the uncyclized CTX fraction from the Mono-S column. After incubation at 65°C for the appropriate time (usually 2 hr), the material was rechromatographed on Mono-S by FPLC as above. CTX with N-terminal pyroglutamate, which elutes earlier than uncyclized CTX, was further purified by reverse-phase HPLC on a C18 column Vydac, 4.6 x 250 mm, S,u). A strong-cation-exchange HPLC column (The Nest Group, Southport, MA, polysulfoethyl aspartamide, 4.6 x 200 mm, 5,u) was used to confirm the purity of the final recombinant CTX.
Planar Bilayer Assay of Native and Recombinant CTX. The channel blocking activity of both native and recombinant CTX was measured on single high-conductance Ca2+-activated K+ channels from rat skeletal muscle inserted into planar bilayers. Lipids, membrane preparation, native venom CTX preparation, and planar bilayer methods were as described (2) . Measurements of CTX blocking and dissociation kinetics of single K+ channels were carried out by observing at least 100 discrete blocking events caused by addition of CTX to the external side of the bilayer. In each experiment, a single channel was incorporated into the planar bilayer by addition of plasma membrane vesicles under osmotic gradients; further channel insertion was suppressed by adjusting the salt concentration to equimolar. The final solutions on the two sides of the membrane were as follows: the internal solution contained 10 mM Hepes (pH 7.4), 150 mM KCl, and 30 ,uM CaC12 and the external solution contained 10 mM Hepes (pH 7.4), 150 mM KCI, 0.1 mM EGTA, bovine serum albumin (30 pug/ml), and the desired concentration of CTX.
Gel Electrophoresis, Immunoblotting, and Analytical Methods. Fusion protein and factor Xa digestion products were analyzed by SDS/polyacrylamide gel electrophoresis on 12% gels and Coomassie brilliant blue staining. Immunoblot analysis was done by electroblotting proteins from the SDS gel onto nitrocellulose filters and treating them with total rabbit antiserum against native venom CTX. Amino acid analysis was done using a Waters Pico-Tag system. The molar extinction coefficients of both the native and the recombinant CTX were calculated based on two amino acid analysis results. The peptide sequencing of the N-terminal uncyclized and cyclized recombinant CTX was performed using an Applied Biosystems model 475A protein sequencer. Before peptide sequencing, cysteine residues of native and the N-terminal cyclized recombinant CTX were reduced with dithiothreitol and carboxamidomethylated with iodoacetamide, and the peptide was deblocked by pyroglutamate aminopeptidase (sequencing grade, Boehringer Mannheim) (19) .
RESULTS
Design and Construction of CTX Gene Expression System. The overall strategy for expressing recombinant CTX in E. coli is indicated in Fig. 1 . The peptide was produced as a fusion protein in which the CTX coding sequence was fused onto the C-terminal portion of the T7 gene 9 protein, as described by Howell and Blumenthal (22) . The tetrapeptide sequence Ile-Glu-Gly-Arg, which is recognized by the "restriction protease" blood coagulation factor Xa, was positioned immediately upstream from the CTX sequence. The N-terminal residue of native CTX is pyroglutamate, which may be formed by nonenzymatic cyclization of N-terminal glutamine. A translation termination codon was inserted at the end of the CTX coding sequence.
The nucleotide sequence encoding the 37 residues of CTX was designed to maximize the number of unique restriction sites. Nine restriction sites in the CTX coding region and four sites in the flanking region were inserted into the gene to facilitate future cassette-mutagenesis studies. Eight chemically synthesized oligonucleotides were individually gelpurified and phosphorylated, and the 5' end groups were confirmed by 5' end analysis. The raphy. After chromatography, the fusion protein was greater than 60% pure as judged by Coomassie staining of SDS/ polyacrylamide gels ( Fig. 2A) . The yield of fusion protein was approximately 30 mg/liter of culture.
The partially purified fusion protein was digested with a sequence-specific protease, blood coagulation factor Xa. Over 24 hr, a major fusion protein band at 42 kDa was gradually split into two products, the gene 9 product portion of the fusion protein at 37 kDa and a small protein at 5 kDa, as seen on Coomassie-stained gels and immunoblots (Fig. 2) . Minor bands in the immunoblot are likely to be nonspecific bacterial proteins cross-reacting with anti-CTX antiserum. The recombinant CTX was further purified by cationexchange chromatography, where a major peak was eluted at approximately 360 mM NaCl. This is slightly later than the elution of native venom CTX (330 mM NaCl), the N terminus of which is blocked by pyroglutamate. Peptide sequencing of the recombinant material confirmed that the first five residues were, as expected, Gln-Phe-Thr-Asn-Val.
With its six cysteines in reduced form, CTX is inactive as a channel-blocker (24) , and so it is necessary to form the three disulfide bonds properly after cleavage of the reduced CTX peptide. We have found that inclusion of a low concentration (0.3-0.5 mM) of 2-mercaptoethanol in the factor Xa cleavage reaction mixture led to complete disulfide formation during this reaction (data not shown). As we demonstrate below, the correct disulfide bonds, yielding fully active material, are formed under these conditions.
To cyclize the N terminus of recombinant CTX to pyroglutamate, we treated the purified toxin with 5% acetic acid for 2 hr at 650C. The N-terminal glutamine was half-converted Since the cyclized and oxidized CTX was fully active, as we show below, we infer that the proper disulfide bonds were formed during this treatment. The oxidized and cyclized recombinant CTX was purified to complete homogeneity on C18 reverse-phase HPLC (Fig. 3B) . The final yield of recombinant CTX was approximately 1 mg/liter of culture.
Chemical Characterization of Recombinant CTX. The amino acid compositions of native and recombinant CTX, shown in Table 1 , were identical within experimental error and were as expected from the sequence ofthe synthetic CTX gene. The 280-nm extinction coefficients of the native and the recombinant CTX were essentially identical (9000 and 9200 M-1 cm-l, respectively). To characterize the recombinant CTX further, several cycles of peptide sequencing were done from its N-terminal end. Without deblocking by pyroglutamate aminopeptidase, no significant sequencing reaction occurred. However, after denaturation, carboxamidomethylation, and cleavage of the N-terminal pyroglutamate, the CTX could be sequenced from the second amino acid residue, phenylalanine.
Functional Activity of Recombinant CTX. The activity of CTX was examined at high resolution by the block of single Ca2+-activated K+ channels (2, 23) . In this assay, shown in ing events, due to binding of single molecules of CTX to the channel, were observed electrically. Statistical distributions of channel dwell-times in the blocked and unblocked states may be calculated from many such blocking events, and toxin association and dissociation rates may be readily measured (1, 2, 23) . The raw data traces of Fig. 4A illustrate these CTX-induced blocking events with preparations of toxin purified from scorpion venom, fully processed recombinant toxin, and uncyclized recombinant toxin at 25 nM, 25 nM, and 75 nM, respectively, in the external medium. It is clear that fully processed recombinant toxin behaved similarly to native venom-purified CTX. The uncyclized peptide was a much poorer inhibitor, for two reasons. (i) The blocks induced by uncyclized recombinant CTX were less frequent than with the other two preparations of CTX. (ii) The blocking events were approximately 5-fold shorter-lived with the uncyclized material.
These qualitative conclusions are supported by a quantitative analysis of the dwell-time distributions for unblocked and blocked states (Fig. 4 B and C ). All these distributions were monoexponential, as demanded for block by a homogeneous preparation of toxin. Both on-rates and off-rates of native and recombinant CTX were identical (Table 2) , with a dissociation constant of 12-15 nM. The uncyclized CTX preparation displayed much weaker channel-blocking activity, with an apparent dissociation constant of 110 nM. The similarity in detailed function of recombinant and native CTX strongly implies the identity in structure of these peptides.
DISCUSSION
We designed and expressed a synthetic gene for CTX based on its primary amino acid sequence. The toxin protein was overexpressed as a cleavable fusion protein with the gene 9 product of phage T7, liberated by a sequence-specific protease, and further processed to the functionally active form of the protein. The Proc. Natl. Acad. Sci. USA 88 (1991) observed in other systems (22) , or by other unknown factors. Aside from stable high-level expression, the gene 9 fusion protein has two other advantages: the high solubility of the fusion protein and the absence of cysteine residues in the fusion vector coding sequence.
After release of CTX from the fusion protein, two additional steps were required for functional activity: formation ofdisulfide bonds and cyclization ofthe N-terminal glutamine to pyroglutamate. Under our preparation conditions (with a low concentration of mercaptoethanol present), oxidation of sulfhydryl groups occurred during the factor Xa digestion. It may seem paradoxical that addition of a thiol should promote disulfide formation; however, dissolved 02 will rapidly oxidize the low amount of mercaptoethanol, which can then efficiently react with protein to form disulfide bonds (25) . After at least 24 hr of incubation in this condition, no free sulfhydryl group was detected. Without N-terminal cyclization, the oxidized CTX showed poor affinity for the Ca2+-activated K+ channel (apparent Kd = 110 nM). Since the NMR-determined structure of the peptide shows the N-terminal pyroglutamate to be lying upon the hydrophobic face of the molecule, positive charge at a free N terminus might plausibly disrupt a hydrophobic interaction between the toxin molecule and the mouth of the channel (20) . More detailed information on the solution structure of recombinant CTX should be obtained from an NMR study. Preliminary onedimensional NMR spectra show virtually identical patterns for recombinant CTX and native toxin (data not shown).
The high-level expression of functionally active CTX, a K+-channel blocker, gives us not only a biochemical tool to study the interaction between CTX and K+-channels but also an example of the utility of the cleavable fusion protein strategy for expressing small proteins of less than 50 %imino acid residues. In addition, because of the experimenter's ability to control many variables, including oxidation and N-terminal cyclization, this could be a useful model system for studying the folding process in small proteins. In the past, we have not been able to investigate in molecular detail the interaction between CTX and K+ channels because of the limited amounts of peptide available from scorpion venom and difficulties in obtaining clean reactions of proteinmodifying reagents with this peptide. By using our expression system in combination with site-directed alterations in the peptide sequence, the molecular basis of CTX recognition by and inhibition of the Ca2+-activated K+ channel may be attacked.
We are grateful to Dr. Dan Oprian for help and advice throughout this work and to Dr. Kenneth Blumenthal for a kind gift of the fusion protein vector pSR9 and advice on its use. This work was supported by National Institutes of Health Grant GM-31768.
